Open AccessReal-World Analysis of the Efficacy and Safety of a Novel Irreversible HER2 Tyrosine Kinase Inhibitor Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer
Author(s) -
Ying Sun,
Beibei Chen,
Jisheng Li,
Ling Peng,
Shuguang Li,
Xiaolong Yu,
Li Li
Publication year - 2021
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s321428
Subject(s) - lapatinib , medicine , metastatic breast cancer , trastuzumab , breast cancer , odds ratio , interquartile range , oncology , cancer , gastroenterology , surgery
As a novel irreversible pan-ErbB inhibitor recently approved in China, pyrotinib has exhibited promising anticancer efficacy and acceptable safety profile in HER2-positive metastatic breast cancer (mBC). The aim of this retrospective study was to estimate the efficacy and safety of pyrotinib treatment in Chinese mBC patients.